The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy.
 
John M. Wrangle
Employment - Precision Genetics
Leadership - Precision Genetics; Tack Bio, LLC
Stock and Other Ownership Interests - Precision Genetics
Patents, Royalties, Other Intellectual Property - Multiple patents pending through the research development office of my University.
Travel, Accommodations, Expenses - Dava Oncology
(OPTIONAL) Uncompensated Relationships - Tack Bio
 
Mary Weber Redman
No Relationships to Disclose
 
Hatim Husain
Consulting or Advisory Role - AstraZeneca; Foundation Medicine; Janssen; Mirati Therapeutics; NeoGenomics Laboratories
Speakers' Bureau - AstraZeneca; Janssen
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Foundation Medicine; Janssen
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech; GlaxoSmithKline; Janssen Oncology; Lilly; Mirati Therapeutics; Novocare; Seagen
Research Funding - Blueprint Medicines; Calithera Biosciences (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)
 
Tom Stinchcombe
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Coherus Biosciences; G1 Therapeutics; Gilead Sciences; Pfizer; Spectrum Pharmaceuticals; Takeda
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Mirati Therapeutics (Inst); Nuvalent, Inc. (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Pfizer
Other Relationship - Genentech; GlaxoSmithKline
 
Martin Joseph Edelman
Stock and Other Ownership Interests - Biomarker Strategies; Creatv MicroTech
Consulting or Advisory Role - BioAtla; Coherus Biosciences; GE Healthcare; Omega Therapeutics
Patents, Royalties, Other Intellectual Property - Patent application for radiopharmaceutical to treat small cell lung cancer. (Inst)
Other Relationship - Anheart Therapeutics; AstraZeneca/MedImmune; Boehringer Ingelheim; Seagen; Takeda
 
Ticiana Leal
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; BMS GmbH & Co. KG; Catalyst Pharmaceuticals; Catalyst Pharmaceuticals; Genentech; Janssen; Jazz Pharmaceuticals; Novartis; Novocure; Novocure; Novocure; Novocure; OncoC4; Pfizer; Regeneron; Regeneron; Roche; Sanofi; Takeda; Takeda
Research Funding - Daiichi Sankyo/Astra Zeneca (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Regeneron; Sanofi
 
Bryan A. Faller
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Celgene; EB SQUIBB; Eisai; Genentech; Lilly; Merck; Novartis; Takeda
 
Katherine Minichiello
No Relationships to Disclose
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Pfizer; Regeneron
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Bayer; Beigene; BerGenBio; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; Genmab; Guardant Health; IO Biotech; ITeos Therapeutics; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; natera; Novartis; oncocyte; Pfizer; PharmaMar; Puma Biotechnology; Regeneron; Rgenix; Sonnet; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Regeneron
Other Relationship - Incyte; Novartis; SpringWorks Therapeutics; Takeda; University of Pennsylvania
 
Karen Kelly
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
 
Roy S. Herbst
Leadership - American Association for Cancer Research; IASLC; Immunocore; Junshi Pharmaceuticals; Society for Immunotherapy of Cancer; SWOG
Stock and Other Ownership Interests - Bolt Biotherapeutics; Checkpoint Therapeutics; Immunocore; Normunity
Consulting or Advisory Role - Abbvie; AstraZeneca; Bolt Biotherapeutics; Bristol-Myers Squibb; Candel Therapeutics; Checkpoint Therapeutics; Cybrexa Therapeutics; DynamiCure Biotechnology; eFFECTOR Therapeutics; EMD Serono; Genentech/Roche; Gilead/Forty Seven; HiberCell; I-Mab; Immune-Onc Therapeutics; Janssen; Johnson and Johnson; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; NextCure; NextCure; Normunity; Novartis; Ocean Biomedical; OncoCyte; Oncternal Therapeutics; Pfizer; Refactor Health; Regeneron; Revelar; Ribon Therapeutics; Sanofi; Seagen; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
Travel, Accommodations, Expenses - American Cancer Society; IASLC; SWOG
 
Jhanelle E. Gray
Honoraria - AstraZeneca; Daiichi Sankyo, Inc; EMD Serono/Merck; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Merck; Merck; OncoCyte; Pfizer; Regeneron; Spectrum ODAC; Triptych Health Partners
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo/UCB Japan; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Jazz Pharmaceuticals; Merck; Merck; Pfizer; Regeneron; Spectrum Pharmaceuticals; Triptych Health Partners
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Services (Inst); Lilly (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Panbela Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Abbvie; OncoCyte; Spectrum Pharmaceuticals